ArticleProceedings of the National Academy of Sciences of the United States of America2019

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Charles Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.